Kinderhook Industries' portfolio company Clinical Research Advantage (CRA) announced today that it has acquired a division of Comprehensive Clinical Development (CCD).

According to the company statement, CRA is the 10^th transaction closed by Kinderhook. The terms of the transaction were not revealed though.

CRA provides Phase II-IV clinical trials management services to both biotech industries and pharmaceutical companies. To date, it has completed more than 10,000 clinical trials.

Meanwhile, the CCD also conducts clinical trials but it is more focused on schizophrenia, depression, bipolar disorder and Alzheimer's.

Chris Michalik, Managing Director of Kinderhook Industries, said the merger of both the CCD and CRA will only boost the company's position as a global leader in trial management organization.

"Both companies have a reputation for delivering a high level of service that their life science partners have come to expect. The acquisition will expand our clinical expertise and breadth of therapeutic capabilities," he said.